Skip to main content
SpringerLink
Log in

Nuovi farmaci per il trattamento dell’ipercolesterolemia

  • Obesità
  • Published:
L'Endocrinologo Aims and scope

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Bibliografia

  1. Cholesterol Treatment Trialists’ (CTT) Collaboration, Baigent C, Blackwell L, Emberson J, Holland LE, Reith C, Bhala N, Peto R, Barnes EH, Keech A, Simes J, Collins R (2010) Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet 376(9753):1670–1681. https://doi.org/10.1016/S0140-6736(10)61350-5

    Article  CAS  PubMed  Google Scholar 

  2. Lambert G, Sjouke B, Choque B, Kastelein JJ, Hovingh GK (2012) The PCSK9 decade. J Lipid Res 53(12):2515–2524. https://doi.org/10.1194/jlr.R026658

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  3. Catapano AL, Graham I, De Backer G, Wiklund O, Chapman MJ, Drexel H, Hoes AW, Jennings CS, Landmesser U, Pedersen TR, Reiner Ž, Riccardi G, Taskinen MR, Tokgozoglu L, Verschuren WM, Vlachopoulos C, Wood DA, Zamorano JL (2016) 2016 ESC/EAS guidelines for the management of dyslipidaemias: the task force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and European Atherosclerosis Society (EAS) developed with the special contribution of the European Assocciation for Cardiovascular Prevention & Rehabilitation (EACPR). Atherosclerosis 253:281–344. https://doi.org/10.1016/j.atherosclerosis.2016.08.018

    Article  CAS  PubMed  Google Scholar 

  4. Robinson JG, Farnier M, Krempf M, Bergeron J, Luc G, Averna M, Stroes ES, Langslet G, Raal FJ, El Shahawy M, Koren MJ, Lepor NE, Lorenzato C, Pordy R, Chaudhari U, Kastelein JJ, ODYSSEY LONG TERM Investigators (2015) Efficacy and safety of alirocumab in reducing lipids and cardiovascular events. N Engl J Med 372(16):1489–1499. https://doi.org/10.1056/NEJMoa1501031

    Article  CAS  PubMed  Google Scholar 

  5. Sabatine MS, Giugliano RP, Wiviott SD, Raal FJ, Blom DJ, Robinson J, Ballantyne CM, Somaratne R, Legg J, Wasserman SM, Scott R, Koren MJ, Stein EA, Open-Label Study of Long-Term Evaluation against LDL Cholesterol (OSLER) Investigators (2015) Efficacy and safety of evolocumab in reducing lipids and cardiovascular events. N Engl J Med 372(16):1500–1509. https://doi.org/10.1056/NEJMoa1500858

    Article  CAS  PubMed  Google Scholar 

  6. Sabatine MS, Giugliano RP, Keech AC, Honarpour N, Wiviott SD, Murphy SA, Kuder JF, Wang H, Liu T, Wasserman SM, Sever PS, Pedersen TR, FOURIER Steering Committee and Investigators (2017) Evolocumab and clinical outcomes in patients with cardiovascular disease. N Engl J Med 376(18):1713–1722. https://doi.org/10.1056/NEJMoa1615664

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Centro per le Malattie Endocrine e Metaboliche, Endocrinologia e Malattie del Metabolismo, Fondazione Policlinico Universitario A. Gemelli, Roma, Italia

    Vinsin A. Sun, Teresa Mezza, Alfredo Pontecorvi & Andrea Giaccari

Authors
  1. Vinsin A. Sun
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Teresa Mezza
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Alfredo Pontecorvi
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Andrea Giaccari
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Andrea Giaccari.

Ethics declarations

Conflitto di interesse

Gli Autori dichiarano di non avere conflitto di interesse.

Consenso informato

Lo studio presentato in questo articolo non ha richiesto sperimentazione umana.

Studi su animali

Lo studio presentato non ha richiesto studi su animali.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Sun, V.A., Mezza, T., Pontecorvi, A. et al. Nuovi farmaci per il trattamento dell’ipercolesterolemia. L'Endocrinologo 19 (Suppl 1), 28–30 (2018). https://doi.org/10.1007/s40619-018-0413-8

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40619-018-0413-8

Search

Navigation